Journal of Medical Bacteriology 2012. 1(3-4):10-16.

A New Approach for Designing a Potentially Vaccine Candidate against Urinary Tract Infection by Using Protein Display on Lactobacillus
Gholamreza Goudarzi, Jalil Fallah-Mehrabadi, Fatemeh Farahani-Hatamabadi, Hedroosha Molla-Agha-Mirzaei, Sarah Najafi

Abstract


Background: The prevalence of Urinary Tract Infection (UTI) is really high in the world. Escherichia coli is a major agent of UTI. One of the strategies for decreasing UTI infections is vaccine development. As the attachment is a really important stage in colonization and infection, at- tachment inhibition has an applied strategy.  FimH protein is a major factor during bacterial colonization in urinary tract and could be used as a vaccine. Thus, it was considered in this research as a candidate anti- gen.
Methods: The sequences of fimH and acmA genes were used for de- signing a synthetic gene. It was cloned to pET23a expression vector and transformed  to E. coli (DE3) Origami.  To confirm the expression  of recombinant  protein,  SDS-PAGE  and western  blotting  methods  were used.  Subsequently,  recombinant  protein  was  purified.  On  the  other hand, Lactobacillus reuteri was cultured and mixed with FimH / AcmA recombinant  protein. The rate of protein localization  on lactobacillus surface was assessed using ELISA method.
Results: It was showed that the recombinant protein was expressed in E. coli (DE3) Origami and purified by affinity chromatography. More- over, this protein could be localized on lactobacillus surface by 5 days.
Conclusion:  In current study,  a fusion recombinant  protein was pre- pared and displayed on L. reuteri surface. This strain could be used for animal  experiment  as  a  competitor  against  Uropathogenic   E.  coli (UPEC). Using manipulated probiotics strains instead of antibiotic ther- apy could decrease the antibiotic consumption  and reduce multi-drug resistant strains.


Keywords


Uropathogenic Escherichia coli, Vaccines, Urinary Tract Infection, Probiotics

Full Text:

PDF

References


Jorgensen I, Seed PC. How to Make It in the Urinary Tract: A Tutorial by Escherichia coli. PLoS Pathog 2012;8(10): e1002907.

Ejernaes K. Bacterial characteristics of importance for recurrent urinary tract infections caused by Escherichia coli. Dan Med Bull 2011; 58 (4): B4187.

Kamal SA, Cao1 Y, Wei DJ. Epide- miologic Investigation of Extra-in- testinal pathogenic E. coli (ExPEC) based on PCR phylogenetic group and fimH single nucleotide polymor- phisms (SNPs) in China. Int J Mol Epidemiol Genet 2011; 2 (4): 339-353.

Saraylu J, Fallah Mehrabadi J, Imani Fooladi AA, et al. Prevalence and Evaluation of Toxin Genes among Uropathogenic Escherichia coli Clin ical Isolates by Duplex PCR. J Med Bacteriol 2012; 1 (1): 17-22.

Hagan EC, Mobley HLT. Uropatho- genic Escherichia coli Outer Mem- brane Antigens Expressed during Urinary Tract Infection. Infect Immun 2007; 75 (8): 3941-9.

Bjorkman I, Berg J, Viberg N, et al.Awareness of antibiotic resistance and antibiotic prescribing in UTI treat- ment: A qualitative study among pri- mary care physicians in Sweden. Scan J Primary Health Care 2013; 31 (1):50-5.

Hopkins WJ, Uehling DT. Vaccine Development for the Prevention of Urinary Tract Infections. Curr Infect Dis Reports 2002; 4(6):509-13.

Ghasem Bagherpour Gh, Imani Foo- ladi AA, Fallah Mehrabadi J, et al. Evaluation of Mammalian Codon Usage of Fimh in DNA Vaccine De- sign. Acta Microbiol Immunol Hung 2011; 58 (4): 259-271.

Dreux N, Denizot J, Martinez-Me- dina M, et al. Point Mutations in FimH Adhesin of Crohn’s Disease- Associated Adherent-Invasive Esch- erichia coli Enhance Intestinal In- flammatory Response. PLoS Pathog 2013; 9 (1): e1003141.

Asadi Karam MR, Oloomi M, Habibi M, Bouzari S. Cloning of fmH and fiC and expression of the fusion pro- tein FimH/FliC from Uro-pathogenic Escherichia coli (UPEC) isolated in Iran. Iranian J Microbiol 2012; 4 (2):55-62.

Mehrabadi JF, Nejad QB, Peerayeh Sh, et al. Construcion of pCDNA-/fimH cassette as a DNA vaccine candidate against urinary tract infec- tion and evaluation of fimH tran- scription in Cos-7 cell line. Res J Mi- crobiol 2009; 4 (2): 75-81.

Reid G, Bruce AW. Probiotics to pre- vent urinary tract infections: the ra- tionale and evidence. World J Urol 2006; 24 (1): 28-32.

Kuroda K, Ueda M. Cell surface en- gineering of yeast for applications in white biotechnology. Biotechnol Lett 2011; 33 (1): 1-9

Yun LL, Tiemann KM, Li Y, et al.Synthetic polymer nanoparticles con- jugated with FimHA from E. coli pili to emulate the bacterial mode of epi- thelial internalization. J Am Chem Soc 2012; 134 (9): 3938-41.

Brumbaugh AR, LT Mobley HLT.Preventing urinary tract infection: progress toward an effective Escheri- chia coli vaccine. Expert Rev Vacc- ines 2012; 11 (6): 663-76.

Schembri MA, Kjaergaard K, Sok- urenko EV, et al. Molecular Cha- racterization of the Escherichia coli FimH Adhesin. J Infect Dis 2001;183 (Suppl 1): S28-S31.

Raha AR, Varma NRS, Yusoff K, et al. Cell surface display system for Lactococcus lactis: a novel develop- ment for oral vaccine. Appl Microbiol Biotechnol 2005; 68 (1): 75.

Lorenzo-Gómez MF, Padillaferna- ndez B, García-Criado FJ, et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogy- necol J 2013; 24 (1): 127-34.

Stapleton AE, Au-Yeung M, Hooton TM, et al. Randomized, Placebo- Controlled Phase 2 Trial of a Lacto- bacillus crispatus Probiotic Given Intravaginally for Prevention of Re- current Urinary Tract Infection. Clin Infect Dis 2011; 52 (10): 1212-7.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.